-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A previous study reported a randomized controlled trial that studied the physical, psychological, and behavioral results of diabetic patients 3 months after treatment, and compared the minimization of blood glucose drift (GEM) and routine weight loss (WL ) in the management of type 2 diabetes (T2D) .
) Therapy .
GEM is a paradigm shift in T2D life>.
.
GEM is a paradigm shift in T2D life>
Blood vessel
Since these GEM groups did not differ in terms of before and after improvements, they were combined for the initial and current analysis
.
Among the participants who completed the evaluation after 3 months, 100% and 96% of the WL and GEM participants completed the 13-month follow-up evaluation
The intra-group comparison before follow-up showed that the body mass index (BMI) of WL participants continued to improve (-0.
9±1.
42% and 52% of WL and GEM participants were classified as responders (individuals whose A1c decreased by at least -0.
The mean and standard deviation of the follow-up change scores (13 months minus baseline) of the outcome variables, within-group analysis showed that only GEM participants had significant continuous improvement in HbA1c (-0.
5%, p<0.
001)
.
Analysis between groups showed that there was no difference between the groups
The mean and standard deviation of the follow-up change scores (13 months minus baseline) of the outcome variables, within-group analysis showed that only GEM participants had significant continuous improvement in HbA1c (-0.
Statistics Although WL responders cannot be predicted, 73% of GEM responders can be predicted by reducing HbA1c, diabetes medication and BMI after pretreatment
The table above shows the changes at 13 months (13 months of follow-up minus baseline), comparing responders and non-responders to the two treatments
.
A responder is defined as any participant who reduces TTE by -0.
The change at 13 months (13 months of follow-up minus baseline) is shown, comparing responders and non-responders to the two treatments
When WL continues to improve BMI, GEM continues to benefit from a wide range of physical, behavioral and psychological parameters, which is beneficial to clinicians and T2D patients
doi: 10.
1136/bmjdrc-2021-002403 leave a message here
